Michael Eckart

Stanford University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index2.7kcitations54works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bacterial Genetics and Biotechnology(8), Hepatitis C virus research(5), Fungal and yeast genetics research(4), Monoclonal and Polyclonal Antibodies Research(4), Bacteriophages and microbial interactions(4)

Publications54 total

Figure S6 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Data from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Tables S1-S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Supplementary Methods S1 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S1 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S5 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S9 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S12 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S7 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S8 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S11 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S4 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S10 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S2 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S3 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Figure S13 from Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
2025Open Access
Abstract B003: Therapeutic targeting of the nuclear pore complex with molecular glue degraders in pancreatic cancer
Cancer Research·2025
Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex
Cancer Discovery·2025Open Access
A Bacterial Toxin Perturbs Intracellular Amino Acid Balance To Induce Persistence
mBio·2021· 25 citedOpen Access
A Localized Complex of Two Protein Oligomers Controls the Orientation of Cell Polarity
mBio·2017· 52 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Linjie Yuan(16), Wenzhi Ji(16), Brendan G. Dwyer(16), Joey Lu(16), Jing Bian(16), Gianna M. Colombo(16), Michael J. Martinez(16), Daniel Fernández(16), Nick A. Phillips(16), Michelle T. Tang(16), Wenjie Zhou(16), Cesar Guzman Huancas(16), Jessica Tran(16), Hannah M. Jones(16), Tian Qiu(16), John G. Doench(16), Matthew G. Rees(16), Jennifer A. Roth(16), Michael D. Cameron(16), Gregory W. Charville(16)